The company has been raising short term funds through commercial papers with maturity of around 3 - 6 months. These are mostly used to reduce the interest rate as CP has lower interest rate compared to working capital bank borrowings. All these funds raised through CP should also be adjusted for the amount repaid as mentioned in their announcements. Furthermore, these are also reflected in the short term borrowings on the balance sheet.
Yes exactly something like that is what I assumed. So can it be so they want to do away with short term borrowings as they have enough share holder capital to use?
Even borrowing through commercial paper is classified as short term borrowings. Nothing to do with share holder capital. There are three major ways through which a company can fund its working capital requirements - internal accruals (cash profits generated during the year), bank and other borrowings and creditors.
so which of these three does this 50 cr fall into ?
Bank and other borrowings.
When is Q1 results will be announced? Do you have any idea?
Q1 results out, pat looks flat yoy… any comments ?
Did anyone attend the AGM? If yes please do share notes !!
Notes from the AGM and talking to management after AGM:
Solid performance over last 3-4 years and big jump in sales from FY16(452cr) to FY17(600cr). Major factors for this performance and its sustainability:
The focus is on what the customer wants – purity, quality and timely delivery every single time apart from price. The chemical industry is very dynamic and one has to be on one’s toes and very close to what the customer wants consistently. The company has been able to do that on a consistent basis which resulted in increased orders. There are a few factors which will make the industry grow on a sustainable basis:
a) Volatility in China in terms of shutting down factories is real. This will lead to structural demand flowing down to India not just in terms of certain chemicals/agrochemicals but also because MNCs have genuinely begun to scout for a viable 2nd alternative. BRL has developed strong relationships with MNCs
b) ‘Make in India’ as well is real, in terms of various policy initiatives and import restrictions that can possibly come shortly
The confluence of China related pollution bans, the Make in India initiatives have given the company a large opportunity to tap. It’s up to the company how they execute and capture this opportunity. The company is very strong in its products and has the confidence of the customers due to its quality and timely delivery but the company needs to keep executing very well. The opportunity cannot help the company if it screw things up in terms of product quality or timely delivery
GST impact has been very good for the group, given a lot of spurious products (domestic as well as import) have reduced considerably
There seem to be 3 segments to our revenue – Domestic sales, Bharat Group Manufacturing, Off-patent manufacturing (domestic and exports within this contract/off-patent manufacturing and MNCs).
During FY17, the revenue growth was major driven by higher domestic sales.
Particulars FY11 FY12 FY13 FY14 FY15 FY16 FY17
Export sales 28.02 27.89 58.30 117.16 120.89 126.49 152.66 25%(growth in FY17)
Sales to group companies 18.87 18.05 25.73 64.45 125.39 126.65 164.84 25%(growth in fy17)
Domestic sales 45.03 94.26 101.53 176.90 189.00 198.97 294.69 50% (growth in fy17)
The big part of 50% growth in domestic sales has happened due to increased supply to MNCs. The supply to MNCs is both in the export and domestic market.
The go-to-market strategy is very clear for the company. The idea to continue to increase supply to MNCs and reduce supply to domestic customers. Of course, the company wants to continue to supply to Category A domestic customers (with requisite margins), but main focus area is to supply to MNCs. The reasons are 2 fold: i) better payment terms and ii) predictability and longevity of the molecule production (if not one, there will always be another).
The contract manufacturing is scaling up and currently accounts for 20-25% of our total revenues. These are usually long term contracts of 3-5 years atleast (and will continue until the company screws up) with raw material price fluctuations being passed on. These are big volume molecules with contract pricing (margins will vary – some molecules will be low margin while some others being high) and that’s part of the business.
Net-net from a revenue perspective, w Exports contributing 25% (~150 cr), Group companies contributing 25% (~150 cr), domestic MNC customers contributing 25% (~150 cr) and rest 25% catered to for domestic non-MNC customers (~150 cr).
Product and growth strategy, Molecule selection:
Meta Phenoxy Benzaldyhyde (top product- almost 80% market share in india and two competitors)
From a Meta Phenoxy Benzaldyhyde perspective, this is an old molecule with limited competition (apart from these players, there is also Meghmani who manufactures MPB). It has a unique customer (1 customer?) with a decent margin . The focus is to restrict production of this molecule to these levels (100 cr) as there are other more profitable molecules that can be manufactured instead of manufacturing this. The company plans to keep producing around these levels (100cr).
There is good potential in Lambda cylothrin as well.
Molecule selection is paramount (and is mostly guess work than a pure science – some times bets come off good, while other times, it doesn’t). The idea is to select niche molecules where there is limited competition and get out of that molecule (and replace it with another) whenever new competition comes in and margins trend down. Management tries to do a good job of this guesswork, but that’s what it is ultimately
The top products composition has not changed much from last year (MPB, Lambda cylathorin, Chlodina etc.). Competition exists in every thing, and the company tries to stay one step ahead of them. The company does not worry too much about market share calculations etc. The main focus is about utilizing capacity to the maximum and manufacture profitable niche molecules, than worry about market sizes and market shares.
The breakup is about 50% pesticides (insecticides and fungicides), 20% intermediates and 30% herbicides currently (as a proportion of revenue). This is expected to continue (as an aside point, Chinese are very strong in the herbicide market).
Company also started supplying Vet APIs to Zoetis. Vet APIs don’t require as much approvals, and the opportunity in this space is ‘good’.
Portion of turnover to MNC and long term contracts:
The proportion of MNCs in the domestic market is 25% and Exports is all MNCs. The strength of companies product and delivery (purity, quality, timely delivery) is of paramount importance to MNCs and the possibilities are endless (either in the domestic or export market) as long as the company don’t screw up and continue to maintain and keep up the product strength and timely delivery. It is upto the company as to how they exploit our association with MNCs
Competition in contract Manufacturing:
MNCs are very focused in terms of purity, product quality and timely delivery. As stated earlier, the limits are endless if you deliver these 3 things consistently and over a period of time. There is a large opportunity – contract manufacturing or otherwise – when you deliver these 3 things and our entire company’s focus is to continue to grow the share of MNCs. How far we can capture, how far we don’t screw up – only time will tell. There are other players as well, but as I said, the market is large, the dynamics of the market (china volatility and make in india) are changing in our favor – so, it’s up to us to capture this space.
New launches (by Bharat Insecticides) in partnership with Nissan:
(Read http://news.agropages.com/News/NewsDetail---22505.htm )
It’s a good opportunity and we will benefit because our group company’s has a tie up with Nissan. No comments on how much it will add to turnover etc.
Patent expiry opportunity in next 3 year:
There is a patent cliff opportunity (many molecules going off-patent in the next few years). The company is actively working on some of those molecules.
Brazil opportunity is very large and you will see some traction later half in the year for Brazil. The company is very positive on the Brazilian opportunity and hope to garner good revenues and margins from that market. The company did not give any target numbers etc. There are no plans of entry into US. Europe will be continue to be steady.
China CAC award:
(Read http://news.agropages.com/News/NewsDetail---22007.htm )
It’s a limited market in China for good quality products with high purity etc along with a good margin. China will not be a large market for BRL to supply there due to payment terms etc. The focus is on other large attractive markets in India and Brazil which serves the purposes of margins and revenues well.
CRAMS of patented molecules:
The company already contract manufacture off-patent molecules for a whole host of MNCs. The company will start manufacturing of patented molecules later half in the year and will try to scale this business up in the subsequent years. These will be new molecules for MNCs which they will be give us and not as replacement for another vendor.
Phasing out low margin products and getting into difficult + high margin molecule happening. What’s the overall trajectory in the product profile
The focus is to increase share of MNC molecules as part of our product profile and reduce domestic company molecules. The focus is to maintain gross margins and EBITDA margins (17-18%) in the future as well because of the strategy in the product and customer profile.
Margin profile/margin sustainability:
The effort is always to work at better margins, but the most important for the company, are payment terms. Post payment terms, the effort will be to utilize as much equipment as possible in the plant. The more equipment used, the more complex the molecule and therefore more margins. Given our focus and strategy, I think these margins should be sustainable, but as stated earlier, agrochem and chemical industry is very dynamic and it is difficult to predict much.
Technical capabilities for backward integration/manufacture more complex molecules like say N-3 / N-4:
Yes, it’s definitely possible. It takes time to build the capabilities, hire the right people and train them but can be done. We are doing 40 cr capex in backward integration, so that should tell you enough.
a) 40 cr capex will be a brownfield expansion in the existing Dahej plant and civil works have already begun. The plant should be completed next year and should reach 100% capacity utilization within the following year post completion. This capex is exclusively to manufacture intermediates and really to backward integrate to i) avoid any China related import risk ii) better margins iii) currently about 55-60% of our RM is imported and we will reduce this dependency drastically due to the 40 cr capex. There is ready demand for the products and selling output from this capex is not a problem. This capex will add to the margins.
b) 200 cr capex will be a greenfield expansion and are scouting for land in the GIDC area. Although there is land space in the existing park, the company completely want to avoid the one-plant-one-area risk and hence would like to go for a greenfield expansion. This would be spread over 3-4 years and nothing immediate. There were no comments on ready customer demand or not for this capex. This capex would be manufacturing intermediates and technicals. There’s been a new rule stating that any factory in a designated chemical area with < 100 acre campus will not have to go for environmental clearance – the new capex will fall in this category, so the company expects that it will not face much delays from environmental clearance (but then again, things are dynamic).
c) 40 cr capex will be one-time. 200 cr capex will be done in phases. First, have to buy the land. Then will do 50 cr capex and fill customer demand and then do subsequent capex etc. The company is very conservative and would like to do incremental capex than do big capex big time and let the capacity sit idle.
d) 40 cr capex will be out of internal accruals. 200 cr capex is still under discussion – if we should do QIP, or fund gradually from internal accruals or take along bank debt. The board is still discussing it and has not made any decision on how we are going to fund it.
Bloated receivables in Sep qtr, bloated inventory in Mar qtr:
Receivables are not bloated as such. The company is very strict on payment terms, and there is no debtor greater than 6 month period. The company can be flexible on margins but not on the payment terms.
Inventory might be higher in March quarter as the company might have stocked more raw material in the face of China RM uncertainty. There is no drastic surprise as such. It’s business as usual.
GST impact for Bharat Insecticides and in turn Bharat Rasayan:
GST impact has been very positive for the entire group as such, given the spurious products (domestic and imports) have taken a large hit. It’s positive for the group, and very positive for BRL
Total capacity and utilization:
Utilization is around 90%, but utilization is a function of what products manufactured. Product mix can be changed at the same utilization to achieve higher revenues and margins.
Dividends and liquidity:
Liquidity in terms of stock split and bonus has been the complaint of many shareholders and will definitely looked into.
Dividends – no comment (but generally, not pro-dividends as there is debt, and we are going for capex. Possibility of a drastic increase in dividends is remote)
Disclosure: Invested: No transactions in last 30 days.
Thanks to a friend who helped in compiling the notes.
There may be error in compiling notes based on our interpretation of what was said during/after agm
Are the promoters of Karuturi Global related to this company anyway?
Bharat Rasayan came out with excellent set of nos during Q3FY18. At a time when other listed agrochemical companies have hardly grown their sales by single digit and their margins have been high by RM price increase, Rasayan came out with strong growth in sales of 45% on a y-o-y basis and further improved its gross as well as PBILDT margins on a q-o-q and y-o-y basis. Company keeps on surprising with its amazing consistency. The analysis of the nos is given below:
*Q3FY17 revenue have been adjusted by excise duty
Great set of numbers…Post GST, decrease in excise duty also played a major role
Post GST implementation, the GST directly gets deducted in revenue. There hasn’t been any reduction in excise duty (GST now) rate.
Care Rating release of June 2018, shows the Working Capital intensiveness of the business and other interesting information